CAPSTONE-1
2018
Baloxavir in Uncomplicated Influenza
In 1,436 outpatients aged 12–64 with uncomplicated influenza, a single dose of baloxavir shortened time to symptom alleviation compared with placebo with much faster viral-load decline.
Result
Primary endpoint: Time to alleviation of symptoms
Median 53.7 h vs 80.2 h (p<0.001). Treatment-emergent PA-I38T/M/F polymerase substitutions in 9.7 % of baloxavir recipients.
- Subtopic
- Influenza
- Design
- Double-blind RCT
- Relevance
- Supporting: context rather than must-know.
- Source
- Hayden FG, et al. N Engl J Med. 2018;379(10):913-923.doi 10.1056/NEJMoa1716197
Discussion & critique
First single-dose, novel-class anti-influenza, used in selected outpatients; resistance signal warrants monitoring.